H.C. Wainwright Maintains Aptose Biosciences(APTO.US) With Buy Rating, Maintains Target Price $7

H.C. Wainwright analyst Joseph Pantginis maintains $Aptose Biosciences(APTO.US)$ with a buy rating, and maintains the target price at $7.According to TipRanks data, the analyst has a success rate of 3

moomoo NewsJun 14 09:31 ET · Ratings

Aptose Presents Tuspetinib (TUS) Clinical and Preclinical Findings at European Hematology Association (EHA) 2024 Hybrid Congress

TUS Monotherapy and TUS+Venetoclax (VEN) Doublet Therapy Show Broad Clinical Activity and Strong Safety Data in relapsed or refractory (R/R) Acute Myeloid Leukemia (AML) and Differentiate TUS from other Investigational

GlobeNewswireJun 14 07:30 ET

Express News | Aptose Biosciences Shares Move Higher; Traders Circulate Zacks Article Titled "Aptose Biosciences Upgraded to Buy: What Does It Mean for the Stock?"

BenzingaJun 13 14:11 ET

H.C. Wainwright Maintains Aptose Biosciences(APTO.US) With Buy Rating, Cuts Target Price to $7

H.C. Wainwright analyst Joseph Pantginis maintains $Aptose Biosciences(APTO.US)$ with a buy rating, and adjusts the target price from $23 to $7.According to TipRanks data, the analyst has a success ra

moomoo NewsJun 11 06:32 ET · Ratings

Aptose Announces Closing of $4.43 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

SAN DIEGO and TORONTO, June 03, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. ("Aptose" or the "Company") (NASDAQ:APTO, TSX:APS), a clinical-stage precision oncology company developing highly differentiated oral

GlobeNewswireJun 3 16:30 ET

Aptose Biosciences Concludes Agreement, Announces Update

TipRanksMay 31 08:58 ET